US President Donald Trump has released a budget ‘blueprint’ for 2018 that could have a major impact on the pharmaceutical and healthcare industries in America.
The President’s ‘skinny budget’, essentially a wish list of spending priorities for legislators to consider, covers about a third of national spending, or $1.5 trillion.
The lightweight document, historically short at only 53 pages, urges major changes to the way the US Food and Drug Administration and the National Institutes of Health (NIH) are funded.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze